公开(公告)号：US20230277556A1

公开(公告)日：2023-09-07

申请号：US18317718

申请日：2023-05-15

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Jane Castelli-Haley ,  Oscar Antunez Flores ,  Keith Gordon ,  Rita Jain ,  Juki Wing-Keung Ng ,  Janine D. North ,  Charlotte D. Owens ,  Hannah Palac ,  Paul M. Peloso ,  Michael C. Snabes ,  Ahmed M. Soliman ,  James W. Thomas ,  Mohamad Shebley

IPC: A61K31/57 ,  A61P15/00 ,  A61K31/513 ,  A61K31/567

CPC classification number: A61K31/57 ,  A61P15/00 ,  A61K31/513 ,  A61K31/567

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US11690854B2

公开(公告)日：2023-07-04

申请号：US17047871

申请日：2018-07-23

Applicant: AbbVie Inc.

Inventor： Juki Wing-Keung Ng ,  Mohamad Shebley

IPC: A61K31/57 ,  A61P15/00 ,  A61K31/513 ,  A61K31/567

CPC classification number: A61K31/57 ,  A61K31/513 ,  A61K31/567 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20240180909A1

公开(公告)日：2024-06-06

申请号：US18494554

申请日：2023-10-25

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley

IPC: A61K31/513 ,  A61K31/565 ,  A61K31/567 ,  A61P15/00 ,  A61P19/00

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/567 ,  A61P15/00 ,  A61P19/00

Abstract: The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

公开(公告)号：US20210308135A1

公开(公告)日：2021-10-07

申请号：US17263009

申请日：2019-08-01

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley

IPC: A61K31/513 ,  A61P19/00 ,  A61P15/00 ,  A61K31/565 ,  A61K31/567

Abstract: The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1- phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

公开(公告)号：US20230414618A1

公开(公告)日：2023-12-28

申请号：US18462054

申请日：2023-09-06

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley ,  Ling Cheng ,  Pooja Manchandani

IPC: A61K31/513 ,  A61P15/00 ,  A61P35/00 ,  A61K9/00 ,  A61K31/567

CPC classification number: A61K31/513 ,  A61P15/00 ,  A61P35/00 ,  A61K9/0053 ,  A61K31/567

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).

公开(公告)号：US20230270744A1

公开(公告)日：2023-08-31

申请号：US18313184

申请日：2023-05-05

Applicant: AbbVie Inc.

Inventor： Farah N. Ali ,  Sheetal P. Dharia ,  Nael M. Mostafa ,  Akshanth R. Polepally ,  Mohamad Shebley

IPC: A61K31/513 ,  A61K31/137 ,  A61K9/00 ,  A61K31/57 ,  A61K31/565 ,  A61K31/4439

CPC classification number: A61K31/513 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/4439 ,  A61K31/565 ,  A61K31/57

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole).

公开(公告)号：US11690845B2

公开(公告)日：2023-07-04

申请号：US17004817

申请日：2020-08-27

Applicant: AbbVie Inc.

Inventor： Farah N. Ali ,  Nael M. Mostafa ,  Ahmed Nader ,  Mohamad Shebley

IPC: A61K31/513 ,  A61K31/137 ,  A61K9/00 ,  A61K31/57 ,  A61K31/565 ,  A61K31/4439

CPC classification number: A61K31/513 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/4439 ,  A61K31/565 ,  A61K31/57

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole).

公开(公告)号：US20250017932A1

公开(公告)日：2025-01-16

申请号：US18903555

申请日：2024-10-01

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley ,  Ling Cheng ,  Pooja Manchandani

IPC: A61K31/513 ,  A61K9/00 ,  A61K31/567 ,  A61P15/00 ,  A61P35/00

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).

公开(公告)号：US20220257597A1

公开(公告)日：2022-08-18

申请号：US17586942

申请日：2022-01-28

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley ,  Ling Cheng ,  Pooja Manchandani

IPC: A61K31/513 ,  A61K9/00 ,  A61P15/00 ,  A61P35/00 ,  A61K31/567

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).

公开(公告)号：US20210275527A1

公开(公告)日：2021-09-09

申请号：US17004817

申请日：2020-08-27

Applicant: AbbVie Inc.

Inventor： Farah N. Ali ,  Sheetal P. Dharia ,  Nael M. Mostafa ,  Ahmed Nader ,  Akshanth R. Polepally ,  Mohamad Shebley

IPC: A61K31/513 ,  A61K31/137 ,  A61K31/4439 ,  A61K31/57 ,  A61K31/565 ,  A61K9/00

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole).